Abstract: The disclosure relates to a driver assistance system for a motor vehicle. The driver assistance system includes a wrong-way driving detection device that detects underway or imminent wrong-way driving of the motor vehicle. The driver assistance system also includes an output device that outputs a signal to a driver of the motor vehicle indicative of a wrong-way driving detection. The driver assistance system, via the output device, is configured to modify an operating state of the infotainment device according to the wrong-way driving detection.

Abstract: The disclosure relates to a driver assistance system for a motor vehicle. The driver assistance system includes a wrong-way driving detection device that detects underway or imminent wrong-way driving of the motor vehicle. The driver assistance system also includes an output device that outputs a signal to a driver of the motor vehicle indicative of a wrong-way driving detection. The driver assistance system, via the output device, is configured to modify an operating state of the infotainment device according to the wrong-way driving detection.

Abstract: The invention features methods, devices, pharmaceutical compositions, and kits for treating or preventing acute vascular leak. Such methods may involve contacting an effective amount of bosutinib for treating or preventing acute vascular leak with a subject in need thereof. Conditions associated with acute vascular leak include ischemic brain injury, stroke, septic shock, anthrax lethal toxin, anaphylaxis, trauma, severe episodic vasculitis, acute lung injury, ventilator-induced lung injury, transfusion-related acute lung injury, acute respiratory distress syndrome, severe burn injury, circulatory shock, capillary leak syndrome, and ischemia-reperfusion injury. The invention also features automatic injection devices, resuscitation fluids, or pharmaceutical compositions comprising an effective amount of bosutinib for treating or preventing acute vascular leak. The invention further features kits for use in the methods of the invention.

Abstract: A pneumatic vehicle tire includes a carcass extending between two bead cores. A belt structure is provided between the carcass and a tread strip which is connected with a pair of sidewalls. A runflat reinforcement is arranged at the inner side of each sidewall. A reinforcer is arranged within each bead portion of the tire. A bead filler extends from the bead ring along the reinforcer. To improve the runflat performance, handling and comfort properties of such a runflat tire, the reinforcer is arranged at the inner side of the bead filler. The reinforcer includes metal cords. The bead filler which extends beyond an end of the reinforcer, is made of a soft rubber compound with an IHRD harness lower than 80.

Abstract: A lancing device for ejecting a lancet having a pricking element protruding therefrom along an ejection axis is provided. The lancing device includes a front cap having an opening facing against an object to be pricked, a lancet holder slideable between a cocked position and a pricking position, and a safety switch moveable between a safety position and a passing position, wherein the pricking element extends beyond the opening when the lancet is ejected; the safety switch prevents the lancet holder form being cocked when the safety switch is in the safety position, and the safety switch allows the lancet holder to be cocked and moved when the safety switch is in the passing position.

Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).

Abstract: A pneumatic vehicle tire includes a carcass extending between two bead cores. A belt structure is provided between the carcass and a tread strip which is connected with a pair of sidewalls. A runflat reinforcement is arranged at the inner side of each sidewall. A reinforcer is arranged within each bead portion of the tire. A bead filler extends from the bead ring along the reinforcer. To improve the runflat performance, handling and comfort properties of such a runflat tire, the reinforcer is arranged at the inner side of the bead filler. The reinforcer includes metal cords. The bead filler which extends beyond an end of the reinforcer, is made of a soft rubber compound with an IHRD hardness lower than 80.

Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).

Abstract: The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I wherein R1 and R2 independently represent H, methyl, C1-C4 acyl, benzoyl R3 represents C1-C4 alkyl or a group of formula CnFmHo, wherein n=1, 2, 3, 4, 5 or 6, m>1, and m+o=2n+1, R4 and R5 in each case represent H or, together, a methylene group or an additional double bond, R6 represents H, R7 represents OH, OC1-C4-alkyl, OC1-C11-acyl or OSO2NR1R2, the dashed lines in the B and C rings of the steroid skeleton additionally representing up to two double bonds, for the production of a medical drug for the treatment of tumor diseases which can be affected positively by inhibiting the tubulin polymerization. The inventive compounds are distinguished by the 2-alkoxy substitution in conjunction with the 17-hydroxy substitution. They have a special effect with regard to inhibiting tubulin polymerization and can be used, for example, for the treatment of prostate cancers.

Abstract: The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention.

Abstract: A lancing device for ejecting a lancet having a pricking element protruding therefrom along an ejection axis is provided. The lancing device includes a front cap having an opening facing against an object to be pricked, a lancet holder slideable between a cocked position and a pricking position, and a safety switch moveable between a safety position and a passing position, wherein the pricking element extends beyond the opening when the lancet is ejected; the safety switch prevents the lancet holder form being cocked when the safety switch is in the safety position, and the safety switch allows the lancet holder to be cocked and moved when the safety switch is in the passing position.

Abstract: The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention. The present invention also provides a device for perfusing tissues and organs with the solutions of the present invention.

Abstract: The present invention relates to a method for the reliable and reproducible preparation of 4-[17?-methoxy-17?-methoxymethyl-3-oxoestra-4,9-dien-11?-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.).

Abstract: The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention.

Abstract: An intravenous tubing and air-separating valve arrangement that prevents the entry of air into the vascular system of a patient during intravenous procedures. Applicable for both pumped and non-pumped intravenous procedures, the effectiveness of the arrangement is dependent on the position of the air-separating valve relative to the patient or pump.

Abstract: The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention. The present invention also provides a device for perfusing tissues and organs with the solutions of the present invention.

Abstract: Methods, systems, and apparatus consistent with the present invention use a beam of laser energy to concentrically form an optical preform from two or more concentric glass objects, such as two glass tubes or a hollow glass tube and a solid glass rod. The glass objects are placed in a concentric configuration where the outer object has an inner surface that is placed proximate to an outer surface of the inner object. Once these are assembled, a beam of laser energy is generated, positioned, and applied to a starting point in the gap defined by the inner surface and the outer surface. Once the laser beam is applied and is reflecting down into the gap, the beam of laser energy is moved relative to the starting point as the beam is concurrently applied. This heats the inner surface and outer surface so that the two objects can be joined to form the optical preform. In another aspect of the invention, a coating layer is disposed within the gap and can be heated by the laser as it is applied within the gap.

Abstract: The invention relates to new C13-substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, wherein R1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R15 represents ethyl, methods of preparing same, and pharmaceutical compositions containing these compounds. The compounds of the invention of general formula I inhibit the activity of steroid sulfatase (EC 3.1.6.2) and do not exhibit any estrogenic effect.

Abstract: The present invention relates to the use of 2-alkoxyestrogen sulfamates of general formula I 1